Barzolvolimab (CDX-0159)
Chronic Spontaneous Urticaria (CSU)
Key Facts
About Celldex Therapeutics
Celldex Therapeutics is a biopharmaceutical company committed to developing novel, targeted therapeutics for devastating diseases, with a primary focus in oncology and inflammatory conditions. Its strategy leverages proprietary antibody platforms to create precision medicines that engage the immune system. Key achievements include advancing barzolvolimab (CDX-0159) into late-stage clinical trials for chronic urticaria and generating compelling clinical data across its pipeline. The company's direction is centered on progressing its lead assets through pivotal studies while exploring their potential in additional indications.
View full company profileAbout Celldex Therapeutics
Celldex Therapeutics is a biopharmaceutical company committed to developing novel, targeted therapeutics for devastating diseases, with a primary focus in oncology and inflammatory conditions. Its strategy leverages proprietary antibody platforms to create precision medicines that engage the immune system. Key achievements include advancing barzolvolimab (CDX-0159) into late-stage clinical trials for chronic urticaria and generating compelling clinical data across its pipeline. The company's direction is centered on progressing its lead assets through pivotal studies while exploring their potential in additional indications.
View full company profileAbout Celldex Therapeutics
Celldex Therapeutics is a biopharmaceutical company committed to developing novel, targeted therapeutics for devastating diseases, with a primary focus in oncology and inflammatory conditions. Its strategy leverages proprietary antibody platforms to create precision medicines that engage the immune system. Key achievements include advancing barzolvolimab (CDX-0159) into late-stage clinical trials for chronic urticaria and generating compelling clinical data across its pipeline. The company's direction is centered on progressing its lead assets through pivotal studies while exploring their potential in additional indications.
View full company profileAbout Celldex Therapeutics
Celldex Therapeutics is a biopharmaceutical company committed to developing novel, targeted therapeutics for devastating diseases, with a primary focus in oncology and inflammatory conditions. Its strategy leverages proprietary antibody platforms to create precision medicines that engage the immune system. Key achievements include advancing barzolvolimab (CDX-0159) into late-stage clinical trials for chronic urticaria and generating compelling clinical data across its pipeline. The company's direction is centered on progressing its lead assets through pivotal studies while exploring their potential in additional indications.
View full company profileTherapeutic Areas
Other Chronic Spontaneous Urticaria (CSU) Drugs
| Drug | Company | Phase |
|---|---|---|
| THB001 | Third Harmonic Bio | Phase 1b |